|   Press Release

Atlas Venture Announces $400 Million Fund XII and Expansion of Partnership


Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, today announced the closing of its twelfth fund, raising $400 million in a highly oversubscribed fundraise. With the closing of Fund XII, Michael Gladstone was promoted to partner. Atlas Venture will continue to advance its mission of doing well by doing good, building biotech companies to deliver high-impact therapies to patients.

Read more.